The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.
Proper control of blood sugar in type 2 diabetes mellitus (T2DM) is not adequate till now in spite of use of well-planned dosage regimens containing oral hypoglycemic agents/insulin or both. Recently, the role of 'incretins,' particularly that of glucagon-like peptide-1 (GLP-1) in glucose homeostasis has been firmly established. The peptide (GLP-1) increases insulin secretion while decreasing that of glucagon in response to rise in plasma glucose in addition to delay of gastric emptying time, reduction of appetite, preservation of beta-cell function, and increase in beta-cell mass all of which will contribute toward lowering of blood sugar in T2DM. But the peptide hormone cannot be used orally as such because of its very short plasma half-life (2 min) and chemical nature, which needs continuous i.v. infusion or repeated s.c. or i.v. injections at short intervals. Hence, to prolong the duration of action of endogenous GLP-1, compounds have been synthesized which inhibit the enzyme dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for metabolic degradation of GLP-1. One such compound is vildagliptin. In this article, an attempt has been made to compile some of the established recent advances in the therapeutic utility of vildagliptin along with a discussion about the physiological role of endogenous GLP-1 and its metabolism by DPP-4.
Department of Microbiology, Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela, Orissa, India.
C K
CK
Chakraborti
Diabetes. 2007 May;56(5):1475-80
17303799
J Pharmacol Exp Ther. 2005 Nov;315(2):688-95
16027230
JAMA. 2007 Jul 11;298(2):194-206
17622601
Curr Med Res Opin. 2007 Jul;23(7):1493-507
17559747
Diabetes Care. 2005 Aug;28(8):1936-40
16043735
Int J Clin Pract Suppl. 2007 Aug;(154):38-48
17593276
Diabetologia. 2005 Sep;48(9):1700-13
16132964
Diabetologia. 2007 Jun;50(6):1148-55
17387446
Curr Med Res Opin. 2007 May;23(5):1131-8
17519080
Lakartidningen. 2005 Feb 21-27;102(8):545-9
15786905
Diabetes Obes Metab. 2005 Nov;7(6):692-8
16219012
J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55
17244786
Diabet Med. 2007 Mar;24(3):223-32
17263764
Diabet Med. 2007 Sep;24(9):955-61
17509069
Verh K Acad Geneeskd Belg. 2001;63(1):5-32; discussion 32-3
11284388
J Clin Pharmacol. 2007 May;47(5):633-41
17442688
J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94
15886245
Diabetes Res Clin Pract. 2007 Apr;76(1):132-8
17223217
Endocrinol Metab Clin North Am. 2001 Dec;30(4):935-82
11727406
Horm Metab Res. 2006 Jun;38(6):423-8
16823726
Diabetes Technol Ther. 2006 Jun;8(3):385-96
16800760
Clin Pharmacokinet. 2007;46(7):577-88
17596103
Indian J Med Res. 2007 Mar;125(3):275-96
17496356
Diabetes Technol Ther. 2005 Aug;7(4):651-7
16120042
Horm Metab Res. 2004 Nov-Dec;36(11-12):867-76
15655721
Eur J Pharmacol. 2005 Oct 3;521(1-3):164-8
16171801
Expert Opin Emerg Drugs. 2004 May;9(1):155-66
15155141
Am J Health Syst Pharm. 2007 Jun;64(12):1265-73
17563048
Eur J Pharm Sci. 2006 May;28(1-2):96-108
16488579
Orv Hetil. 2007 Apr 1;148(13):579-87
17383951
Drugs. 2006;66(15):1989-2001; discussion 2002-4
17100408
Diabetes Care. 2007 Apr;30(4):890-5
17277036
Postepy Hig Med Dosw (Online). 2006;60:15-23
16407790
Int J Clin Pract Suppl. 2007 Aug;(154):19-28
17593274
Diabetologia. 2005 Apr;48(4):616-20
15770466
Pharmacotherapy. 2006 Mar;26(3):360-74
16503716
Expert Opin Investig Drugs. 2006 Apr;15(4):431-42
16548792
Trends Pharmacol Sci. 2003 Jul;24(7):377-83
12871671
Int J Clin Pract. 2006 Nov;60(11):1454-70
17073841
Diabetes Care. 2006 Feb;29(2):435-49
16443905
Lancet. 2006 Nov 11;368(9548):1696-705
17098089
Rev Med Liege. 2007 Apr;62(4):217-21
17566392
Curr Med Res Opin. 2007 Apr;23(4):919-31
17407649
Clin Pharmacokinet. 2007;46(9):787-802
17713976
Ann Pharmacother. 2007 May;41(5):824-32
17456545
Adv Pharmacol. 2005;52:151-71
16492545
Treat Endocrinol. 2005;4(6):361-70
16318402
Int J Clin Pract Suppl. 2007 Aug;(154):29-37
17593275
Expert Opin Emerg Drugs. 2006 Sep;11(3):525-39
16939389
Diabetes. 2007 Jan;56(1):8-15
17192459
Expert Opin Investig Drugs. 2004 Sep;13(9):1091-102
15330741
Drugs Today (Barc). 2006 Aug;42(8):519-31
16969429
Eur J Clin Pharmacol. 2007 Jul;63(7):677-86
17486328